Immune profiling for translational research

One assay. Countless applications.

How researchers are using the Maxpar Direct Immune Profiling Assay

Fluidigm CyTOF® technology and the Maxpar® Direct™ Immune Profiling Assay™ provide best-in-class immune monitoring with the cost, flexibility and consistency needed for standardized immune monitoring.

Look through the publications, preprints and clinical trials listed below to see the number of ways that researchers are using the assay to advance their studies of COVID-19 and other diseases and conditions.

Webinar | A Complete Immune Monitoring Solution with CyTOF: Ideal for Pandemics and Beyond

Presenter: Frederik De Smet, MSc, PhD Assistant Professor, University of Leuven


‘Impaired type I interferon activity and exacerbated inflammatory responses in severe COVID-19 patients’
Hadjadj, J. et al. Science 369 (2020): 718–724.

Read publication

Read the Spotlight article on Benjamin Terrier, lead author of this publication, to see how his lab used this immune profiling assay to define a distinct immune response phenotype in severe and critically ill COVID-19 patients that could help identify high-risk individuals.

"Analyzing the immune response of patients … by mass cytometry allows us to cover the innate and adaptive immune responses simultaneously. Not only could we analyze immune cells, but also cytokine production and the transcriptional signatures in these patients. Essentially, we could look at everything in the whole blood.”
Benjamin Terrier, MD, PhD, University of Paris

‘High-dimensional single-cell analysis reveals the immune characteristics of COVID-19’
Shi, W. et al. American Journal of Physiology: Lung Cellular and Molecular Physiology (2020): doi:10.1152/ajplung.00355.2020.

‘A streamlined CyTOF workflow to facilitate standardized multi-site immune profiling of COVID-19 patients’
Geanon, D. et al. medRxiv (2020): doi:10.1101/2020.06.26.20141341

‘Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity’
Ausar, S.F. et al. Communications Biology 3 (2020): 427

‘A human circulating immune cell landscape in aging and COVID-19’
Zheng, Y. et al. Protein Cell (2020): doi:10.1007/s13238-020-00762-2.

‘Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity’
Vanderbeke, L. et al. Research Square (2020):doi:0.21203/

Use of the assay in clinical trials

IMPACC (Immunophenotyping Assessment in a COVID-19 Cohort) Clinical Study

The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) clinical study (NCT04378777) is a prospective observational cohort surveillance study of up to 2,000 adult participants hospitalized with known or presumptive COVID-19. Detailed analysis of the immunophenotypic and genomic data collected will be used to identify key features of COVID-19 disease susceptibility and/or progression.

High-parameter mass cytometry panels will be used to analyze immune cell frequencies and activation states in both peripheral whole blood and endotracheal aspirate samples over time (see 10-minute recorded webinar by Ruth Montgomery, Yale University).

Two key advantages make mass cytometry ideal for gathering this data: the ability to stain, freeze and ship samples processed with the Maxpar Direct Immune Profiling Assay to a centralized location for processing on a mass cytometer and the ability to analyze small sample sizes, such as endotracheal aspirates.

Learn more about how mass cytometry and the Maxpar Direct Immune Profiling Assay are being used in the IMPACC study.
Read the press release

COntAGIous (COVID-19 Advanced Genetic and Immunologic Sampling) Trial

A large collaboration led by the research university KU Leuven and University Hospital Leuven has initiated the COntAGIouS trial (COVID-19 Advanced Genetic and Immunologic Sampling), an in-depth characterization of the dynamic host immune response to coronavirus SARS-CoV-2.

What makes this study so significant is the multiplexing approach, simultaneously analyzing different cells, proteins and RNA biomarkers in blood samples, with the objective to dive into the unknowns of COVID-19. CyTOF technology, together with the Maxpar Direct Immune Profiling Assay, plays an important role in the trial, helping the team to observe the different immune system players and their interactions in COVID-19 patient samples.

Read more about this study in an article in

Hear from lead researcher Frederik De Smet as he presents early data from this clinical study.

Watch webinar

Antidepressant Trial with P2X7 Antagonist JNJ-54175446 (ATP)

A multi-institutional collaborative study in the United Kingdom is using the Maxpar Direct Immune Profiling Assay for participant immunomonitoring in a clinical trial for major depressive disorder.

Patients who have not responded to conventional antidepressant drugs will be treated with an anti-inflammatory drug to reduce stress-related depression. The assay will be used to assess changes in peripheral blood at baseline and after eight weeks of daily treatment.

Lori Turner, a researcher at the University of Cambridge, explains why her team selected the Maxpar Direct Immune Profiling System for standardized immune profiling in this clinical study.

Read the interview

Contact us

Complete the form below to talk to a Field Applications Specialist about panel design for my unique research project or to learn more about the Maxpar Direct Immune Profiling System.

* You may withdraw your consent anytime in every email you will receive from us. To learn more about how we use your information, read our Privacy Policy.

For Research Use Only. Not for use in diagnostic procedures.